NCT03444103View on ClinicalTrials.gov

A Pilot Trial of Clazakizumab in Late ABMR

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 16, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Antibody-mediated Rejection
Interventions
DRUG

Clazakizumab / Clazakizumab

Humanized monoclonal anti-IL-6 antibody

DRUG

Placebo / Clazakizumab

0.9% Saline

Trial Locations (2)

1090

Medical University of Vienna, Vienna

10117

Charité University, Berlin

Sponsors

Collaborators (1)

CSL Behring
All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

collaborator

University of Alberta

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

lead

Medical University of Vienna

OTHER